A court has delivered a loss for Germany-based B. Braun Melsungen, dismissing its allegations that US-based device manufacturer Becton Dickinson infringed three of its intravenous catheter patents and ruling the patents invalid.
The Australian Securities and Investments Commission claims Rio Tinto’s former CFO was referring to the write down for the reserves for two coal assets that were part of a $4 billion acquisition of Rio Tinto Coal Mozambique when he sent an email to the company CEO in January 2012 that contained the phrase “worse by far than expected”.
Maurice Blackburn’s battle with the Australian Taxation Office over a tax bill on class action settlements for thousands of Black Saturday bushfire victims went to court Tuesday, and the landmark case may turn on whether or not the law firm’s administration of the settlement distribution scheme counts as a business.
A judge has found the former director of Sydney-based insolvency practice CRS Warner Kugel is entitled to compensation after he was “ambushed” out of the firm in 2014.
A court has signed off on a $2.6 million settlement in a class action against Endeavour Energy and two other companies over the 2013 Mt Victoria bushfires that will leave class members empty-handed.
The Federal Court has thrown out a proposed $35 million settlement between ASIC and Westpac over responsible lending breaches, saying the agreement was “unworkable” and left the court in an “information vacuum”.
A judge has adjourned an application by law firm Slater & Gordon for a common fund order in a class action against the Commonwealth Bank and its wealth management unit, amid two landmark challenges to the courts’ powers to make such orders.
Murray Goulburn and its former CEO have reached a settlement with the Australian Competition and Consumer Commission over claims the dairy producer misled farmers in three states about farmgate milk prices.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.
Litigation funder Regency Funding has sought leave to intervene as a major player in one of two challenges to the courts’ powers to issue common fund orders in class actions, but it might have a fight on its hands.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
